Skip to main content

Table 4 Correlation between YAP, PRKCI, and PRKCZ mRNA levels and the clinicopathological features of LAC patients

From: Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma

Characteristics

Patients

YAP

Patients

PRKCI

  

PRKCZ

 

No. (%)

Low

High

P

No. (%)

Low

High

P

No. (%)

Low

High

P

Sex

   

0.026

   

0.445

   

0.140

 Male

30 (51)

22 (63)

8 (33)

 

25 (52)

21 (50)

4 (67)

 

29 (52)

16 (44)

13 (65)

 

 Female

29 (49)

13 (37)

16 (67)

 

23 (48)

21 (50)

2 (33)

 

27 (48)

20 (56)

7 (35)

 

Age

   

0.143

   

0.788

   

0.081

 < 60

13 (22)

10 (29)

3 (13)

 

10 (21)

9 (21)

1 (17)

 

13 (23)

11 (31)

2 (10)

 

 ≥ 60

46 (78)

25 (71)

21 (88)

 

38 (79)

33 (79)

5 (83)

 

43 (77)

25 (69)

18 (90)

 

Pathological stage

   

0.010

   

0.592

   

0.035

 I-II

52 (88.1)

34 (97)

18 (75)

 

43 (90)

38 (91)

5 (83)

 

49 (88)

34 (94)

15 (75)

 

 III-IV

7 (12)

1 (3)

6 (25)

 

5 (10)

4 (10)

1 (17)

 

7 (13)

2 (6)

5 (25)

 

Histological subtype

   

0.803

   

0.877

   

0.088

 Acinar

50 (85)

30 (86)

20 (83)

 

41 (85)

36 (56)

5 (83)

 

48 (86)

33 (92)

15 (75)

 

 Lepidic

9 (15)

5 (14)

4 (17)

 

7 (15)

6 (14)

1 (17)

 

8 (14)

3 (8)

5 (25)

 

Distant metastasis

   

0.223

   

NA

   

0.176

 Absent

58 (98)

35 (100)

23 (96)

 

42 (100)

42 (100)

6 (100)

 

55 (98)

36 (100)

19 (95)

 

 Present

1 (2)

0 (0)

1 (4)

 

0

0

0

 

1 (2)

0 (0)

1 (5)

 

Chemotherapy

   

0.342

   

0.445

   

0.625

 Not done

35 (59)

19 (54)

16 (67)

 

25 (52)

21 (50)

4 (67)

 

34 (61)

21 (58)

13 (65)

 

 Done

24 (41)

16 (46)

8 (33)

 

23 (48)

21 (50)

2 (33)

 

22 (39)

15 (42)

7 (35)

 

EGFR

   

0.853

   

0.016

   

0.836

 Wild

33 (57)

19 (56)

14 (58)

 

26 (54)

20 (48)

6 (100)

 

32 (58)

20 (57)

12 (60)

 

 Mutant

25 (43)

15 (44)

10 (42)

 

22 (46)

22 (52)

0 (0)

 

23 (42)

15 (43)

8 (40)

 
  1. EGFR, Epidermal growth factor receptor; Chemotherapy, Post-surgical chemotherapy; NA, not applicable